Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Aquestive Therapeutics, Inc is a biotechnology business based in the US. Aquestive Therapeutics shares (AQST) are listed on the NASDAQ and all prices are listed in US Dollars. Aquestive Therapeutics employs 232 staff and has a trailing 12-month revenue of around USD$59.3 million.
Since the stock market crash in March caused by coronavirus, Aquestive Therapeutics's share price has had significant positive movement.
Its last market close was USD$6.23, which is 32.26% up on its pre-crash value of USD$4.22 and 341.84% up on the lowest point reached during the March crash when the shares fell as low as USD$1.41.
If you had bought USD$1,000 worth of Aquestive Therapeutics shares at the start of February 2020, those shares would have been worth USD$463.28 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,577.19.
|Latest market close||USD$6.23|
|52-week range||USD$1.41 - USD$10|
|50-day moving average||USD$6.6771|
|200-day moving average||USD$5.5118|
|Wall St. target price||USD$14.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.605|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-18)||-0.64%|
|1 month (2020-10-23)||18.44%|
|3 months (2020-08-25)||-22.03%|
|6 months (2020-05-22)||8.35%|
|1 year (2019-11-25)||-17.37%|
|2 years (2018-11-23)||-38.92%|
|3 years (2017-11-22)||N/A|
|5 years (2015-11-22)||N/A|
|Revenue TTM||USD$59.3 million|
|Gross profit TTM||USD$32.2 million|
|Return on assets TTM||-37.7%|
|Return on equity TTM||-3347.45%|
|Market capitalisation||USD$169.1 million|
TTM: trailing 12 months
There are currently 1.9 million Aquestive Therapeutics shares held short by investors – that's known as Aquestive Therapeutics's "short interest". This figure is 25.1% up from 1.5 million last month.
There are a few different ways that this level of interest in shorting Aquestive Therapeutics shares can be evaluated.
Aquestive Therapeutics's "short interest ratio" (SIR) is the quantity of Aquestive Therapeutics shares currently shorted divided by the average quantity of Aquestive Therapeutics shares traded daily (recently around 1.6 million). Aquestive Therapeutics's SIR currently stands at 1.19. In other words for every 100,000 Aquestive Therapeutics shares traded daily on the market, roughly 1190 shares are currently held short.
However Aquestive Therapeutics's short interest can also be evaluated against the total number of Aquestive Therapeutics shares, or, against the total number of tradable Aquestive Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aquestive Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Aquestive Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0964% of the tradable shares (for every 100,000 tradable Aquestive Therapeutics shares, roughly 96 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aquestive Therapeutics.
Find out more about how you can short Aquestive Therapeutics stock.
We're not expecting Aquestive Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aquestive Therapeutics's shares have ranged in value from as little as $1.41 up to $10. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aquestive Therapeutics's is 3.8483. This would suggest that Aquestive Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.